Barclays analyst Etzer Darout raised the firm’s price target on Oruka Therapeutics (ORKA) to $50 from $48 and keeps an Overweight rating on the shares post the Q4 report. The firm is positive on shares ahead of the Phase 2 data next quarter, with a “clear benchmark” from Skyrizi. ORKA-002 development continues to progress, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Oruka Therapeutics reports Q4 EPS (45c), consensus (62c)
- Oruka’s ORKA-001 Extension Study Builds Long-Term Case in Psoriasis Market
- Is ORKA a Buy, Before Earnings?
- Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
- Oruka Therapeutics price target raised to $45 from $42 at Wedbush